Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mostaghim Anahita, Minkove Samuel, Aguilar-Company Juan, Ruiz-Camps Isabel, Eremiev-Eremiev Simeon, Dettorre Gino M, Fox Laura, Tondini Carlo, Brunet Joan, Carmona-García MCarmen, Lambertini Matteo, Bower Mark, Newsom-Davis Thomas, Sharkey Rachel, Pria Alessia Dalla, Rossi Maura, Plaja Andrea, Salazar Ramon, Sureda Anna, Prat Aleix, Michalarea Vasiliki, Van Hemelrijck Mieke, Sita-Lumsden Ailsa, Bertuzzi Alexia, Rimassa Lorenza, Rossi Sabrina, Rizzo Gianpiero, Pedrazzoli Paolo, Lee Alvin Jx, Murphy Cian, Belessiotis Katherine, Diamantis Nikolaos, Mukherjee Uma, Pommeret Fanny, Stoclin Annabelle, Martinez-Vila Clara, Bruna Riccardo, Gaidano Gianluca, D'Avanzo Francesca, Gennari Alessandra, Athale Janhavi, Eichacker Peter, Pinato David J, Torabi-Parizi Parizad, Cortellini Alessio, OnCovid study group
Аннотация
METHODS: The OnCovid registry (NCT04393974) was searched from February 27, 2020, to January 31, 2022, for patients who received systemic anti-cancer therapy in the 4 weeks before laboratory-confirmed COVID-19 diagnosis. Propensity-score matching using country, vaccination status, primary tumor type, sex, age, comorbidity burden, tumor stage, and remission status investigated differences in predefined clinical outcomes comparing those who had or had not received ICIs.
RESULTS: Of 3523 patients screened, 137 ICI-only and 1378 non-ICI met inclusion criteria. Before matching, ICI patients were older, male, enrolled at centers in Italy, and had histories of smoking, thoracic cancers, advanced cancer stages, and active malignancies (P ≤0.02). After matching, there were 120 ICI and 322 non-ICI patients. ICI patients had no differences (odds ratio: 95% CI) in presenting COVID-19 symptoms (0.69: 0.37-1.28), receipt of COVID-specific therapy (0.88: 0.54-1.41), 14-day (0.95: 0.56-1.61), or 28-day (0.79: 0.48-1.29) mortalities. However, ICI patients required less COVID-19-related hospitalization (0.37: 0.21-0.67) and oxygen therapy (0.51: 0.31-0.83) and developed fewer complications (0.57: 0.36-0.92).
CONCLUSION: In this propensity-score matched analysis, previous ICI therapy did not worsen and potentially improved COVID-19 outcomes in patients with cancer.